Investment
Features
FeesSafety
Academy
More
Pluang+

Valhi trades at 36% NAV discount with no clear catalyst for price recovery soon

Market News
08 Jul 2026
Seeking Alpha
View Source
Bearish
Valhi trades at 36% NAV discount with no clear catalyst for price recovery soon

Valhi, Inc. is currently trading at a roughly 36% discount to its net asset value (NAV), with no obvious catalyst expected to close this gap soon. The company faces margin pressures in Q2 due to higher energy costs impacting its chemicals segment, although rising titanium dioxide prices may partially offset this. Demand concerns in key markets like property and homebuilding could limit upside potential for Valhi's core products. NAV discounts can persist indefinitely without specific market triggers, suggesting caution for investors expecting a quick rebound.

More News

Copper explorers in British Columbia use electrical surveys to identify promising drill targets amid rising copper prices.

Copper explorers in British Columbia use electrical surveys to identify promising drill targets amid rising copper prices.

Copper exploration in British Columbia is increasingly relying on induced polarization (IP) geophysical surveys, which measure electrical chargeability and resistivity in rocks to identify sulphide mineralization associated with copper deposits. Gold...

Market News
Bullish
35 minutes ago
S&P 500 rises 30.6% in first 20 months of Trump's second term, nearing first term gains.

S&P 500 rises 30.6% in first 20 months of Trump's second term, nearing first term gains.

The S&P 500 index has increased by 30.6% during the first 20 months of Donald Trump's second presidential term, slightly surpassing the 28.5% gain recorded in the same period of his first term. This comparison is significant for investors as it provi...

Market News
Neutral
1 hour ago
Citigroup raises Krystal Biotech price target on Vyjuvek sales and promising KB113 trial results

Citigroup raises Krystal Biotech price target on Vyjuvek sales and promising KB113 trial results

Citigroup increased its price target for Krystal Biotech to $416 from $386, citing strong Q2 revenue of $119.2 million from its approved product Vyjuvek and encouraging early clinical data for KB113, a treatment for basal cell carcinomas in Gorlin sy...

Analyst Insights
Bullish
1 hour ago
Bank7 beats Q3 earnings estimates but revenue dips; merger with Century Financial set to close soon

Bank7 beats Q3 earnings estimates but revenue dips; merger with Century Financial set to close soon

Bank7 Corp. reported Q3 2026 earnings of $1.06 per share, slightly beating analyst estimates, while revenue of $23.37 million fell short and declined year-over-year. Despite lower revenue and earnings compared to last year, the bank continues to grow...

Company Fundamentals
Neutral
1 hour ago
Scotiabank raises Targa Resources price target to $319, citing strong momentum and a $1.25 dividend.

Scotiabank raises Targa Resources price target to $319, citing strong momentum and a $1.25 dividend.

Scotiabank increased its price target for Targa Resources to $319 from $314, indicating a potential 12.7% upside from the current share price of around $283. Targa Resources, a key player in the midstream energy sector, is recognized as a top momentu...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App